AKT as locus of cancer positive feedback loops and extreme robustness

Journal of Cellular Physiology

Volumn 228, Issue 3, 2013, Pages 522-524

  Radisavljevic, Ziv ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; HYDROXYLATION; LEUKEMIA; LEUKEMOGENESIS; LYMPHOMA; METASTASIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UBIQUITINATION; UPREGULATION; WALDENSTROEM MACROGLOBULINEMIA;

FEEDBACK, PHYSIOLOGICAL; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OXIDANTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84870417482     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24167     Document Type: Review

References (46)

1. Brown JM, Giaccia AJ. 1998. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416.
2. Carlson JM, Doyle J. 1999. Highly optimized tolerance: A mechanism for power laws in designed systems. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics 60:1412-1427.
3. Carlson JM, Doyle J. 2002. Complexity and robustness. Proc Natl Acad Sci USA 99:2538-2545.
4. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N. 2010. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 9:963-975.
5. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. 2002. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387-3394.
6. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. 2009. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 69:4567-4572.
7. Dewhirst MW, Cao Y, Moeller B. 2008. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425-437.
8. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. 2010. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: Implications for disease progression. Blood 115:1755-1764.
9. Giatromanolaki A, Harris AL., 2001. Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res 21:4317-4324.
10. Graeber T, Osmanian C, Jacks T. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91.
11. Gray LH, Conger AD, Ebert M. 1953. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648.
12. Harris AL. 2002. Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
13. Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M. 2004. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 10:6686-6694.
14. Jain RK. 2005. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62.
15. Kiyatkin A, Aksamitiene E, Markevich NI, Borisov NM, Hoek JB, Kholodenko BN. 2006. Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. J Biol Chem 281:19925-19938.
16. Koong AC, Denko NC, Hudson KM. 2000. Canditate genes for the hypoxic tumour phenotype. Cancer Res 60:883-887.
17. Kuo SH, Yeh PY, Chen LT, Wu MS, Lin CW, Yeh KH, Tzeng YS, Chen JY, Hsu PN, Lin JT, Cheng AL. 2008. Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood 112:2927-2934.
18. Mahajan K, Mahajan NP. 2012. PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics. J Cell Physiol 227:3178-3184.
19. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A, McCubrey JA. 2010. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 1803:991-1002.
20. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G. 2000. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45:72-79.
21. Metzen E, Zhou J, Jelkmann W, Fandrey J, Brune B. 2003. Nitric oxide impairs normoxic degradation of HIF-1a by inhibition of prolyl hydroxylases. Mol Biol Cell 14:3470-3481.
22. Misra S, Ghatak S, Toole BP. 2005. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2 J Biol Chem 280:20310-20315.
23. Naik E, Dixit VM. 2011. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med 208:417-420.
24. Park SJ, Jeon YJ. 2012. Dieckol from Ecklonia cava suppresses the migration and invasion of HT1080 cells by inhibiting the focal adhesion kinase pathway downstream of Rac1-ROS signaling. Mol Cells 33:141-149.
25. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D. 2010. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95:819-828.
26. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. 2003. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361.
27. Powis G, Kirkpatrick L. 2004. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 3:647-654.
28. Pries AR, Höpfner M, le Noble F, Dewhirst MW, Secomb TW. 2010. The shunt problem: Control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 10:587-593.
29. Radisavljevic Z. 2003. Nitric oxide suppression triggers apoptosis through the FKHRL1 (FOXO3a)/ROCK kinase pathway in human breast carcinoma cells. Cancer 97:1358-1363.
30. Radisavljevic Z. 2004a. Locus of fragility in robust breast cancer system. J Cell Biochem 92:711-715.
31. Radisavljevic Z. 2004b. Inactivated tumor suppressor Rb by nitric oxide promotes mitosis in human breast cancer cells. J Cell Biochem 92:1-5.
32. Radisavljevic Z. 2008. AKT as locus of fragility in robust cancer system. J Cell Biochem 104:2071-2077.
33. Radisavljevic Z. 2012. AKT as locus of cancer angiogenic robustness and fragility. J Cell Physiol. DOI: 10.1002/jcp.24167 [Epub ahead of print].
34. Radisavljevic Z, Gonzalez-Flecha B. 2003. Signaling through Cdk2, importin-alpha and NuMA is required for H2O2-induced mitosis in primary type II pneumocytes. Biochim Biophys Acta Mol Cell Res 1640:163-170.
35. 2-induced mitosis. J Cell Biochem 91:1293-1300.
36. Radisavljevic Z, Avraham H, Avraham S. 2000. Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem 275:20770-20774.
37. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. 2010. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115:559-569.
38. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732.
39. Singh M, Martinez AR, Govindaraju S, Lee BS. 2012. HuR inhibits apoptosis by amplifying Akt signaling through a positive feedback loop. J Cell Physiol. DOI: 10.1002/jcp.24120 [Epub ahead of print].
40. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR. 1996. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metabol 81:411-420.
41. Trusolino L, Comoglio PM. 2002. Scater-factor and semaphoring receptors: Cell signaling for invasive growth. Nat Rev Cancer 2:289-300.
42. Wu WS. 2006. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 25:695-705.
43. 2 signaling pathways for human cholangiocarcinoma cell growth. J Biol Chem 281:33982-33996.
44. Yamauchi Y, Furukawa K, Hamamura K, Furukawa K. 2011. Positive feedback loop between PI3K-Akt-mTORC1 signaling and the lipogenic pathway boosts Akt signaling: Induction of the lipogenic pathway by a melanoma antigen. Cancer Res 71:4989-4997.
45. Zhou T, Carlson JM, Doyle J. 2002. Mutation, specialization, and hypersensitivity in highly optimized tolerance. Proc Natl Acad Sci USA 99:2049-2054.
46. Zhou X, Li D, Resnick MB, Behar J, Wands J, Cao W. 2011. Signaling in H2O2-induced increase in cell proliferation in Barrett's esophageal adenocarcinoma cells. J Pharmacol Exp Ther 339:218-227.